Literature DB >> 30316080

A new drug carrier with oxygen generation function for modulating tumor hypoxia microenvironment in cancer chemotherapy.

Zhe Zhang1, Na Niu2, Xi Gao1, Fuqin Han1, Zhijun Chen3, Shujun Li3, Jian Li3.   

Abstract

Hypoxia is the main characteristic of tumor microenvironment, and the one of the key factors that cause the drug resistance of cancer cells for chemotherapy. Anticancer drug such as DOX cannot react with sufficient oxygen to produce reactive oxygen species (ROS) in hypoxic environment, which affects the therapeutic efficiency of the drug. In this work, we constructed a multi-functional nano-carrier (named as FeSiAuO) containing Fe3O4, mesoporous SiO2 and Au2O3 with magnetic, large surface ratio and light induced oxygen production properties. The Au2O3 may decompose into oxygen (O2) and Au under the light irradiation to improve the oxygen concentration of the microenvironment of cancer cells, which increases the sensitivity of cancer cells to drug (DOX), reduces the drug resistance, and effectively exerts the anticancer effect of DOX. Meanwhile, the release of the as-loaded DOX molecule from the porous of SiO2 will be also promoted under light irradiation in diverse pH conditions. With the helping of the magnet effect of the Fe3O4, the DOX can be also targeted delivered to the tumor site under the magnetic field. All of above results were thoroughly examined by the cell and small animal assays, which demonstrate that the FeSiAuO can be served as the multifunctional drug nano-carrier to achieve the targeted high-efficient cancer therapy.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Au(2)O(3); Chemotherapy; Drug release; Magnetic Fe(3)O(4); Oxygen generation function

Mesh:

Substances:

Year:  2018        PMID: 30316080     DOI: 10.1016/j.colsurfb.2018.10.008

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  6 in total

Review 1.  Polymer nanoparticle-assisted chemotherapy of pancreatic cancer.

Authors:  Tianqi Su; Bo Yang; Tianren Gao; Tongjun Liu; Jiannan Li
Journal:  Ther Adv Med Oncol       Date:  2020-05-08       Impact factor: 8.168

Review 2.  Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.

Authors:  Wei Li; Anghui Peng; Huajun Wu; Yingyao Quan; Yong Li; Ligong Lu; Min Cui
Journal:  Front Immunol       Date:  2020-12-21       Impact factor: 7.561

3.  Hypoxia represses early responses of prostate and renal cancer cells to YM155 independent of HIF-1α and HIF-2α.

Authors:  David Danielpour; Sarah Corum; Scott M Welford; Eswar Shankar
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-12-23

4.  Development of Hif1a Pharmacogenomic Mutation Models to Study Individual Variations in Drug Action for Tumor Hypoxia: An in Silico Approach.

Authors:  Vaisali Balasubramaniam; P K Krishnan Namboori
Journal:  J Pharm Bioallied Sci       Date:  2022-03-04

Review 5.  Oxygen-Based Nanocarriers to Modulate Tumor Hypoxia for Ameliorated Anti-Tumor Therapy: Fabrications, Properties, and Future Directions.

Authors:  Xianqiang Li; Yue Wu; Rui Zhang; Wei Bai; Tiantian Ye; Shujun Wang
Journal:  Front Mol Biosci       Date:  2021-07-01

Review 6.  Recent Advancements in Nanomedicine for 'Cold' Tumor Immunotherapy.

Authors:  Qinjun Chen; Tao Sun; Chen Jiang
Journal:  Nanomicro Lett       Date:  2021-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.